Julia Carnevale

Julia Carnevale

Auto-generated profile, based on publicly available information

Julia Carnevale

Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in Nature
Verified
Journal Article
Closed access
PDF file
TRTheodore L. Roth
Theodore L. Roth
CPCristina Puig-Saus
Cristina Puig-Saus
RYRuby Yu
Ruby Yu
ESEric Shifrut
Eric Shifrut
JCJulia Carnevale
Julia Carnevale
AMAlex Marson
Alex Marson

1 December 2018 in Cell
Verified
Journal Article
Closed access
ESEric Shifrut
Eric Shifrut
JCJulia Carnevale
Julia Carnevale
VTVictoria Tobin
Victoria Tobin
TRTheodore L. Roth
Theodore L. Roth
JWJonathan M. Woo
Jonathan M. Woo
AMAlex Marson
Alex Marson

24 August 2022 in Nature
Verified
Journal Article
Open access
PDF file
JCJulia Carnevale
Julia Carnevale
ESEric Shifrut
Eric Shifrut
NKNupura Kale
Nupura Kale
WNWilliam A. Nyberg
William A. Nyberg
FBFranziska Blaeschke
Franziska Blaeschke
AMAlex Marson
Alex Marson
The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints1,2. Targeted gene editing has the potential to overcome these limitations and enhance T cell therapeutic function3–10. Here we performed multiple genome-wide CRISPR knock-out screens under different immunosuppressive conditions to identify genes that can be targeted to prevent T cell dysfunction. These screens converged on RASA2, a RAS GTPase-activating protein (RasGAP) that we identify as a signalling checkpoint in human T cells, which is downregulated upon acute T cell receptor stimulation and can increase gradually with chronic antigen exposure. RASA2 ablation enhanced MAPK signalling and chimeric antigen receptor (CAR) T cell cytolytic activity in response to target antigen. Repeated tumour antigen stimulations in vitro revealed that RASA2-deficient T cells show increased activation, cytokine production and metabolic activity compared with control cells, and show a marked advantage in persistent cancer cell killing. RASA2-knockout CAR T cells had a competitive fitness advantage over control cells in the bone marrow in a mouse model of leukaemia. Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours. Together, our findings highlight RASA2 as a promising target to enhance both persistence and effector function in T cell therapies for cancer treatment.

15 September 2023 in Cell
Verified
Journal Article
Open access
FBFranziska Blaeschke
Franziska Blaeschke
YCYan Yi Chen
Yan Yi Chen
RARyan Apathy
Ryan Apathy
BDBence Daniel
Bence Daniel
ACAndy Y. Chen
Andy Y. Chen
AMAlex Marson
Alex Marson
Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors (SRs). Over 30 ModPoKI screens across human TCR- and CAR-T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct that enhanced fitness of chronically stimulated CAR-T cells and anti-cancer function in vitro and in vivo. ModPoKI's modularity allowed us to generate an ∼10,000-member library of TF combinations. Non-viral KI of a combined BATF-TFAP4 polycistronic construct enhanced fitness. Overexpressed BATF and TFAP4 co-occupy and regulate key gene targets to reprogram T cell function. ModPoKI facilitates the discovery of complex gene constructs to program cellular functions.

18 March 2026 in Nature
Verified
Journal Article
Open access
PDF file
WNWilliam A. Nyberg
William A. Nyberg
PBPierre-Louis Bernard
Pierre-Louis Bernard
WNWayne Ngo
Wayne Ngo
CWCharlotte H. Wang
Charlotte H. Wang
JAJonathan Ark
Jonathan Ark
JEJustin Eyquem
Justin Eyquem
Engineered T cells, reprogrammed to express chimeric antigen receptors (CAR) or T cell receptors (TCR), have transformed cancer treatment and are being explored as therapeutics for autoimmune and infectious diseases. Enhancing T cell function through genome editing, either by disrupting endogenous genes or precisely inserting DNA payloads, has shown considerable promise 1 . However, the ex vivo manufacturing process is lengthy and costly, limiting accessibility of these therapies. In vivo generation of CAR T cells could overcome these barriers, but current methods rely either on transient expression with limited durability, or on random integration of DNA payloads that lack specificity. Here we demonstrate that stable and cell-specific transgene expression can be achieved through in vivo site-specific integration of large DNA payloads. We developed a two-vector system to deliver CRISPR–Cas9 ribonucleoproteins and a DNA donor template, using enveloped delivery vehicles and adeno-associated viruses, respectively. We optimized both vectors for T cell-specific delivery and gene-targeting efficiency. By integrating a CAR transgene into a T cell-specific locus, we generate therapeutic levels of CAR T cells in vivo in humanized mouse models of B cell aplasia, and haematological and solid malignancies. These findings offer a pathway to more efficient, precise and widely accessible T cell therapies.

28 March 2013 in Leukemia
Verified
Journal Article
Open access
PDF file
JCJ Carnevale
J Carnevale
LRL Ross
L Ross
APAlexandre Puissant
Alexandre Puissant
VBV Banerji
V Banerji
RSR M Stone
R M Stone
KSK Stegmaier
K Stegmaier
Spleen tyrosine kinase (SYK) was recently identified as a new target in acute myeloid leukemia (AML); however, its mechanistic role in this disease is poorly understood. Based on the known interaction between SYK and mammalian target of rapamycin (mTOR) signaling in lymphoma, we hypothesized that SYK may regulate mTOR signaling in AML. Both small-molecule inhibition of SYK and SYK-directed shRNA suppressed mTOR and its downstream signaling effectors, as well as its upstream activator, AKT. Moreover, the inhibition of multiple nodes of the phosphatidylinositol 3′-kinase (PI3K) signaling pathway enhanced the effects of SYK suppression on AML cell viability and differentiation. Evaluation of the collateral mitogen-activated protein kinase (MAPK) pathway revealed a heterogeneous response to SYK inhibition in AML with downregulation of MEK and extracellular signal–regulated kinase (ERK) phosphorylation in some AML cell lines but a paradoxical increase in MEK/ERK phosphorylation in RAS-mutated AML. These studies reveal SYK as a regulator of mTOR and MAPK signaling in AML and demonstrate that inhibition of PI3K pathway activity enhances the effects of SYK inhibition on AML cell viability and differentiation.